Research & Development
AGC to acquire MPC manufacturing plant in Spain
4 December 2018 -

Chemicals company AGC Inc revealed on Tuesday the launch of an agreement to acquire Malgrat Pharma Chemicals SLU (MPC) from Boehringer Ingelheim.

MPC, a subsidiary of Boehringer Ingelheim, manufactures synthetic pharmaceutical active ingredients for the group. MPC manufactures cGMP compliant commercialized synthetic pharmaceuticals as well as compounds in clinical development on a range of scales.

Through the acquisition of MPC, AGC said it will have its first US FDA-registered site in Europe in the synthetic pharmaceutical CDMO business. The acquisition will provide AGC with a foothold in Europe as well as broaden its Pharma CDMO Business.

Leveraging AGC's fluorination technologies and extensive experience in in-house drug discovery and the CDMO business built up in Japan, AGC, with the addition of MPC, will be able to offer its CDMO services from a broader asset base, catering to European customer requirements and expanding its presence in the European market.

The acquisition is subject to approval from the relevant antitrust authorities and the fulfilment of closing conditions under the share purchase agreement.



Related Headlines